Maxillofacial Plastic and Reconstructive Surgery

Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지
DOI QR코드

DOI QR Code

Reconstruction of Defect after Treatment of Bisphosphonate-related Osteonecrois of the Jaw with Staged Iliac Bone Graft

  • Ahn, Kyo-Jin (Department of Oral and Maxillofacial Surgery, Section of Dentistry, Seoul National University Bundang Hospital) ;
  • Kim, Young-Kyun (Department of Oral and Maxillofacial Surgery, Section of Dentistry, Seoul National University Bundang Hospital) ;
  • Yun, Pil-Young (Department of Oral and Maxillofacial Surgery, Section of Dentistry, Seoul National University Bundang Hospital)
  • Received : 2013.11.27
  • Accepted : 2014.02.25
  • Published : 2014.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Bisphosphonate is used widely for osteoporosis treatment, but a rising concern is the risk of osteonecrosis after long-term bisphosphonate use. Such cases are increasing, suggesting a need for research to prevent and treat bisphosphonate-related osteonecrosis of jaws. A 63-year-old female took bisphosphonate (Fosamax$^{(R)}$) for four years for treatment of osteoporosis and stopped medication two months ago because of unhealed wound. She was treated with marginal mandibulectomy maintaining the inferior border, and a metal plate was placed to prevent mandible fracture. Four months after the mandibulectomy, mandible reconstruction surgery using iliac bone and allograft was done. Six months after reconstruction, implant placement and treatment with an overdenture was done without complications. This study presents a case with a successful result.

Keywords

References

  1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  2. American Association of Oral and Maxillofacial Surgeons: 2006 Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws [Internet]. Rosemont (IL): American Association of Oral and Maxillofacial Surgeons [cited 2006 Sep 25]. Available from: http://www.aaoms.org/docs/position_papers/osteonecrosis.pdf.
  3. Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws: American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw-2009 Update. Approved by the Board of Trustees [Internet]. Rosemont (IL): American Association of Oral and Maxillofacial Surgeons [cited 2009 Jan 15]. Available from:http://www.aaoms.org/docs/position_papers/bronj_update.pdf.
  4. Bisphosphonate Related Osteonecrosis of the JAW (BRONJ), Position Statement of Korea [Internet]. Seoul: Korean Endocrine Society [cited 2009 Jun 25]. Available from: http://www.kaoms.org/file/BRONJ_Korea_Position_Statement.pdf.
  5. Yoshimura H, Ohba S, Nakamura M, Sano K. Mandibular reconstruction using iliac bone and great auricular nerve grafts and oral rehabilitation using osseointegrated implants in a patient with a large ossifying fibroma: a 10-year follow-up study. J Oral Maxillofac Surg 2013;71:2176-88. https://doi.org/10.1016/j.joms.2013.04.034
  6. Mucke T, Haarmann S, Wolff KD, Holzle F. Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction. J Craniomaxillofac Surg 2009;37:291-7. https://doi.org/10.1016/j.jcms.2008.12.004
  7. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7. https://doi.org/10.1200/JCO.2005.02.8670
  8. Mattheos N, Caldwell P, Petcu EB, Ivanovski S, Reher P. Dental implant placement with bone augmentation in a patient who received intravenous bisphosphonate treatment for osteoporosis. J Can Dent Assoc 2013;79:d2.
  9. Grbic JT, Landesberg R, Lin SQ, et al; Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008;139:32-40. https://doi.org/10.14219/jada.archive.2008.0017
  10. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-69. https://doi.org/10.1016/j.oraloncology.2007.11.012
  11. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 2008;139:23-30. https://doi.org/10.14219/jada.archive.2008.0016
  12. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA; American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008;139:1674-7. https://doi.org/10.14219/jada.archive.2008.0110
  13. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009;140:61-6. https://doi.org/10.14219/jada.archive.2009.0019
  14. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-60. https://doi.org/10.1111/j.1600-0714.2006.00391.x
  15. Walter C, Grotz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15:197-202. https://doi.org/10.1007/s00520-006-0120-z
  16. Stockmann P, Vairaktaris E, Wehrhan F, et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010;18:449-60. https://doi.org/10.1007/s00520-009-0688-1
  17. Pautke C, Bauer F, Otto S, et al. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. J Oral Maxillofac Surg 2011;69:84-91. https://doi.org/10.1016/j.joms.2010.07.014
  18. Marx RE. Reconstruction of defects caused by bisphosphonateinduced osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:S107-19.
  19. Ferretti C, Rikhotso E, Muthray E, Reyneke J. Interim reconstruction and space maintenance of mandibular continuity defects preceding definitive osseous reconstruction. Br J Oral Maxillofac Surg 2013;51:319-25. https://doi.org/10.1016/j.bjoms.2012.06.012